These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 23887863)

  • 1. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
    Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
    Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.
    Sasaki M; Matsubara T; Yoneda N; Nomoto K; Tsuneyama K; Sato Y; Nakanuma Y
    Histopathology; 2013 Feb; 62(3):446-57. PubMed ID: 23163606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
    Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
    Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
    Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
    Nakagawa S; Okabe H; Ouchi M; Tokunaga R; Umezaki N; Higashi T; Kaida T; Arima K; Kitano Y; Kuroki H; Mima K; Nitta H; Imai K; Hashimoto D; Yamashita YI; Chikamoto A; Baba H
    HPB (Oxford); 2018 Oct; 20(10):939-948. PubMed ID: 29759640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.
    Sasaki M; Yamaguchi J; Itatsu K; Ikeda H; Nakanuma Y
    J Pathol; 2008 Jun; 215(2):175-83. PubMed ID: 18393368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
    Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
    Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
    Alimova I; Birks DK; Harris PS; Knipstein JA; Venkataraman S; Marquez VE; Foreman NK; Vibhakar R
    Neuro Oncol; 2013 Feb; 15(2):149-60. PubMed ID: 23190500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma.
    Zhang J; Chen L; Han L; Shi Z; Zhang J; Pu P; Kang C
    Cancer Lett; 2015 Jan; 356(2 Pt B):929-36. PubMed ID: 25444902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer.
    Ishikawa S; Hayashi H; Kinoshita K; Abe M; Kuroki H; Tokunaga R; Tomiyasu S; Tanaka H; Sugita H; Arita T; Yagi Y; Watanabe M; Hirota M; Baba H
    Int J Cancer; 2014 Dec; 135(11):2528-36. PubMed ID: 24346863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3.
    Tang B; Du J; Li Y; Tang F; Wang Z; He S
    Med Oncol; 2014 Nov; 31(11):271. PubMed ID: 25280519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery.
    Shi RY; Yang XR; Shen QJ; Yang LX; Xu Y; Qiu SJ; Sun YF; Zhang X; Wang Z; Zhu K; Qin WX; Tang ZY; Fan J; Zhou J
    Cancer; 2013 Mar; 119(5):993-1003. PubMed ID: 23132676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
    Zhou W; Wang J; Man WY; Zhang QW; Xu WG
    Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
    Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
    Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis.
    Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A
    Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
    Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
    Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.